SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 895.12 |
| Enterprise Value ($M) | 940.54 |
| Book Value ($M) | 56.10 |
| Book Value / Share | 1.53 |
| Price / Book | 15.96 |
| NCAV ($M) | -138.53 |
| NCAV / Share | -3.78 |
| Price / NCAV | -6.46 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.12 |
| Return on Assets (ROA) | -0.07 |
| Return on Equity (ROE) | -0.36 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 0.85 |
| Current Ratio | 0.91 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 169.53 |
| Assets | 364.16 |
| Liabilities | 308.07 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 199.61 |
| Operating Income | 9.07 |
| Net Income | -17.48 |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -22.20 |
| Cash from Investing | -33.16 |
| Cash from Financing | 28.53 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13D/A | Baum Mark L | 10.69 | 16.30 | |
| 13G/A | Kaufman Daniel Louis | 4.75 | -11.69 | |
| 13G/A | Ophir Asset Management Pty Ltd | 2.80 | -59.64 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 320,691 | 1,058,779 | 30.29 | |
| 154,003 | 792,371 | 19.44 | |
| 71,575 | 274,677 | 26.06 | |
| 90,895 | 333,206 | 27.28 | |
| 110,414 | 338,641 | 32.61 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| GANX – Gain Therapeutics, Inc. | GHRS – GH Research PLC |
| HRMY – Harmony Biosciences Holdings, Inc. | IKNA – Ikena Oncology, Inc. |
| IMRX – Immuneering Corporation |
Financial data and stock pages provided by
Fintel.io